Insider Buying: Bausch Health Companies Inc (NYSE:BHC) Insider Purchases 30,703 Shares of Stock

Share on StockTwits

Bausch Health Companies Inc (NYSE:BHC) insider William D. Humphries acquired 30,703 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $21.18 per share, with a total value of $650,289.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NYSE:BHC opened at $22.10 on Friday. Bausch Health Companies Inc has a twelve month low of $17.20 and a twelve month high of $28.45. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 8.94. The business has a 50 day moving average price of $23.29 and a two-hundred day moving average price of $23.83. The company has a market cap of $7.48 billion, a P/E ratio of 4.99, a price-to-earnings-growth ratio of 0.25 and a beta of 0.76.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The firm had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period last year, the company earned $0.93 EPS. The company’s revenue was up 1.1% compared to the same quarter last year. As a group, analysts anticipate that Bausch Health Companies Inc will post 4.24 earnings per share for the current fiscal year.

BHC has been the subject of several research analyst reports. Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies and gave the company a “buy” rating in a research report on Tuesday, June 11th. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research report on Monday, July 15th. Mizuho set a $45.00 price objective on Bausch Health Companies and gave the company a “buy” rating in a research report on Thursday, June 20th. Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research report on Tuesday, May 21st. Finally, Cantor Fitzgerald set a $32.00 price objective on Bausch Health Companies and gave the company a “buy” rating in a research report on Friday, May 31st. Three analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. Bausch Health Companies has a consensus rating of “Buy” and a consensus price target of $29.68.

Large investors have recently added to or reduced their stakes in the business. Highstreet Asset Management Inc. acquired a new position in Bausch Health Companies during the 1st quarter worth approximately $354,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bausch Health Companies by 1.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 193,792 shares of the company’s stock valued at $4,783,000 after buying an additional 2,223 shares during the last quarter. CLARET ASSET MANAGEMENT Corp boosted its holdings in shares of Bausch Health Companies by 9.2% in the 1st quarter. CLARET ASSET MANAGEMENT Corp now owns 14,751 shares of the company’s stock valued at $364,000 after buying an additional 1,245 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock valued at $91,441,000 after buying an additional 815,311 shares during the last quarter. Finally, Academy Capital Management Inc. TX boosted its holdings in shares of Bausch Health Companies by 3.9% in the 1st quarter. Academy Capital Management Inc. TX now owns 580,218 shares of the company’s stock valued at $14,331,000 after buying an additional 21,641 shares during the last quarter. 57.35% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: How much can an individual set aside as a catch-up contribution?

Insider Buying and Selling by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NXT-ID  Given Hold Rating at Maxim Group
NXT-ID Given Hold Rating at Maxim Group
Orchard Therapeutics  Stock Rating Lowered by Zacks Investment Research
Orchard Therapeutics Stock Rating Lowered by Zacks Investment Research
Premier Financial Bancorp  Rating Increased to Hold at BidaskClub
Premier Financial Bancorp Rating Increased to Hold at BidaskClub
Oppenheimer Begins Coverage on Papa John’s Int’l
Oppenheimer Begins Coverage on Papa John’s Int’l
Ritter Pharmaceuticals  Downgraded by ValuEngine
Ritter Pharmaceuticals Downgraded by ValuEngine
Sandy Spring Bancorp  Raised to Hold at BidaskClub
Sandy Spring Bancorp Raised to Hold at BidaskClub


© 2006-2019 Ticker Report